KMT2B-linked dystonia (DYT-KMT2B) is a childhood-onset dystonia syndrome typically beginning in the lower limbs and progressing caudocranially to affect the upper limbs with eventual prominent craniocervical involvement. Despite its recent recognition, it now appears to be one of the more common monogenic causes of dystonia syndromes. Here, we present an atypical case of DYT-KMT2B with oromandibular dystonia as the presenting feature, which remained restricted to this region three decades after symptom onset. This appears to be the first reported case of DYT-KMT2B from Southeast Asia and provides further supporting evidence for the pathogenic impact of the KMT2B c.6210_6213delTGAG variant.
Kah Hui Yap, Nurul Husna Baharudin, Abdul Halim Abdul Gafor, Rabani Remli, Shen-Yang Lim, Wan Asyraf Wan Zaidi, Shahrul Azmin, Shahizon Azura Mohamed Mukari, Raihanah Abdul Khalid, Norlinah Mohamed Ibrahim
J Mov Disord. 2022;15(3):258-263. Published online May 26, 2022
Objective The basal ganglia (BG) are susceptible to fluctuations in blood urea levels, sometimes resulting in movement disorders. We described patients with end-stage kidney disease (ESKD) presenting with movement disorders associated with bilateral BG lesions on imaging.
Methods We report four patients and systematically reviewed all published cases of ESKD presenting with movement disorders and bilateral BG lesions (EBSCOhost and Ovid).
Results Of the 72 patients identified, 55 (76.4%) were on regular dialysis. Parkinsonism was the most common movement disorder (n = 39; 54.2%), followed by chorea (n = 24; 33.3%). Diabetes mellitus (n = 51; 70.8%) and hypertension (n = 16; 22.2%) were the most common risk factors. Forty-three (59.7%) were of Asian ethnicity. Complete clinical resolution was reported in 17 (30.9%) patients, while 38 (69.1%) had incomplete clinical resolution with relapse. Complete radiological resolution occurred in 14 (34.1%) patients.
Conclusion Movement disorders associated with BG lesions should be recognized as a rare and potentially reversible metabolic movement disorder in patients with ESKD.
Jia Wei Hor, Shen-Yang Lim, Eng Soon Khor, Kah Kian Chong, Sze Looi Song, Norlinah Mohamed Ibrahim, Cindy Shuan Ju Teh, Chun Wie Chong, Ida Normiha Hilmi, Ai Huey Tan
J Mov Disord. 2022;15(2):106-114. Published online December 24, 2021
Objective Converging evidence suggests that intestinal inflammation is involved in the pathogenesis of neurodegenerative diseases. Previous studies on fecal calprotectin in Parkinson’s disease (PD) were limited by small sample sizes, and literature regarding intestinal inflammation in multiple system atrophy (MSA) is very scarce. We investigated the levels of fecal calprotectin, a marker of intestinal inflammation, in PD and MSA.
Methods We recruited 169 subjects (71 PD, 38 MSA, and 60 age-similar nonneurological controls). Clinico-demographic data were collected. PD and MSA were subtyped and the severity assessed using the MDS-UPDRS and UMSARS, respectively. Fecal calprotectin and blood immune markers were analyzed.
Results Compared to controls (median: 35.7 [IQR: 114.2] μg/g), fecal calprotectin was significantly elevated in PD (median: 95.6 [IQR: 162.1] μg/g, p = 0.003) and even higher in MSA (median: 129.5 [IQR: 373.8] μg/g, p = 0.002). A significant interaction effect with age was observed; between-group differences were significant only in older subjects (i.e., ≥ 61 years) and became more apparent with increasing age. A total of 28.9% of MSA and 18.3% of PD patients had highly abnormal fecal calprotectin levels (≥ 250 μg/g); however, this difference was only significant for MSA compared to controls. Fecal calprotectin correlated moderately with selected blood immune markers in PD, but not with clinical features of PD or MSA.
Conclusions Elevated fecal calprotectin suggests a role for intestinal inflammation in PD and MSA. A more complete understanding of gut immune alterations could open up new avenues of research and treatment for these debilitating diseases.
Citations
Citations to this article as recorded by
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic Ai Huey Tan, Shen Yang Lim, Anthony E. Lang Nature Reviews Neurology.2022; 18(8): 476. CrossRef
The Gut Microbiome–Brain Crosstalk in Neurodegenerative Diseases Laura Ghezzi, Claudia Cantoni, Emanuela Rotondo, Daniela Galimberti Biomedicines.2022; 10(7): 1486. CrossRef
Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin? Angela Saviano, Marcello Candelli, Christian Zanza, Andrea Piccioni, Alessio Migneco, Veronica Ojetti Medicina.2022; 58(10): 1384. CrossRef
Consideration for Hemiballismus in the Differential Diagnosis: A Rare Case of Hyperosmolar Hyperglycemic State Iman Isayli, Nicolas Ulloa, John Childress Cureus.2022;[Epub] CrossRef
A Case of Diabetic Hemichorea Hemiballismus Exacerbated by Hypoglycemia Jessica Rupp, Avrum Gillespie AACE Clinical Case Reports.2021;[Epub] CrossRef
Hemicorea inducida por hiperglucemia no cetósica: discordancia clínicorradiológica Juan Pablo García Marmolejo, Manuel David Mayoral Valencia, Paola Andrea Tejada Serna Universitas Médica.2021;[Epub] CrossRef
White matter and cerebellar involvement in alternating hemiplegia of childhood Mariasavina Severino, Livia Pisciotta, Domenico Tortora, Benedetta Toselli, Michela Stagnaro, Ramona Cordani, Giovanni Morana, Anna Zicca, Svetlana Kotzeva, Clelia Zanaboni, Giovanni Montobbio, Andrea Rossi, Elisa De Grandis Journal of Neurology.2020; 267(5): 1300. CrossRef
Atypical and early symptoms of sporadic Creutzfeldt – Jakob disease: case series and review of the literature Grammatiki Katsikaki, Ioannis E. Dagklis, Petros Angelopoulos, Dimitrios Ntantos, Angeliki Prevezianou, Sevasti Bostantjopoulou International Journal of Neuroscience.2021; 131(9): 927. CrossRef
Review of Hereditary and Acquired Rare Choreas Daniel Martinez-Ramirez, Ruth H. Walker, Mayela Rodríguez-Violante, Emilia M. Gatto Tremor and Other Hyperkinetic Movements.2020;[Epub] CrossRef
A Case of Creutzfeldt-Jakob Disease Presented as Rapid Progressive Parkinsonism Yoonah Park, Chan-Nyeong Lee Dementia and Neurocognitive Disorders.2019; 18(4): 152. CrossRef
Purposeless groaning has been reported in advanced progressive supranuclear palsy. We present a case of purposeless groaning occurring as a primary complaint in a patient with advanced Parkinson’s disease. Purposeless groaning is thought to be a manifestation of disinhibition and perseveration due to frontal-subcortical dysfunction. Proper recognition of this phenomenon will help clinicians to avoid unnecessary investigations and treatment (e.g., prescription of opioid medications).
Citations
Citations to this article as recorded by
Involuntary moaning in a Hispanic family with eight affected members Maria Gisatulin, Malco Rossi, Claudia Perandones, Christine Klein, Katja Lohmann, Marcelo Merello Parkinsonism & Related Disorders.2021; 89: 206. CrossRef
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy Jung E. Park JAMA Neurology.2020; 77(12): 1569. CrossRef
Clinical Phenotype of LRRK2 R1441C in 2 Chinese Sisters Shen-Yang Lim, Jia Lun Lim, Azlina Ahmad-Annuar, Katja Lohmann, Ai Huey Tan, Kai Bin Lim, Yi Wen Tay, Yee Lee Shing, Kalai Arasu Muthusamy, Peter Bauer, Arndt Rolfs, Christine Klein Neurodegenerative Diseases.2020; 20(1): 39. CrossRef
The spectrum of involuntary vocalizations in humans: A video atlas Tina Mainka, Bettina Balint, Felix Gövert, Lille Kurvits, Christoph Riesen, Andrea A. Kühn, Marina A.J. Tijssen, Andrew J. Lees, Kirsten Müller‐Vahl, Kailash P. Bhatia, Christos Ganos Movement Disorders.2019; 34(12): 1774. CrossRef
We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accumulation. The patient harbored a novel mutation in the WDR45 gene. A detailed video and description of her clinical condition are provided. Her movement disorder phenomenology was characterized primarily by limb stereotypies and gait dyspraxia. The patient’s disability was advanced by the time iron-chelating therapy with deferiprone was initiated, and no clinical response in terms of cognitive function, behavior, speech, or movements were observed after one year of treatment.
Citations
Citations to this article as recorded by
Quantitative retrospective natural history modeling of WDR45-related developmental and epileptic encephalopathy – a systematic cross-sectional analysis of 160 published cases Afshin Saffari, Julian Schröter, Sven F. Garbade, Julian E. Alecu, Darius Ebrahimi-Fakhari, Georg F. Hoffmann, Stefan Kölker, Markus Ries, Steffen Syrbe Autophagy.2022; 18(7): 1715. CrossRef
Cerebral Iron Deposition in Neurodegeneration Petr Dusek, Tim Hofer, Jan Alexander, Per M. Roos, Jan O. Aaseth Biomolecules.2022; 12(5): 714. CrossRef
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders Rachel M. Wise, Annika Wagener, Urban M. Fietzek, Thomas Klopstock, Eugene V. Mosharov, Fabio A. Zucca, David Sulzer, Luigi Zecca, Lena F. Burbulla Neurobiology of Disease.2022; 175: 105920. CrossRef
WDR45 variants cause ferrous iron loss due to impaired ferritinophagy associated with nuclear receptor coactivator 4 and WD repeat domain phosphoinositide interacting protein 4 reduction Kiwako Tsukida, Shin-ichi Muramatsu, Hitoshi Osaka, Takanori Yamagata, Kazuhiro Muramatsu Brain Communications.2022;[Epub] CrossRef
Iron Chelation in Movement Disorders: Logical or Ironical Dinkar Kulshreshtha, Jacky Ganguly, Mandar Jog Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2021; : 1. CrossRef
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders Vassilena Iankova, Ivan Karin, Thomas Klopstock, Susanne A. Schneider Frontiers in Neurology.2021;[Epub] CrossRef
Consensus clinical management guideline for beta‐propeller protein‐associated neurodegeneration Jenny L Wilson, Allison Gregory, Manju A Kurian, Ittai Bushlin, Fanny Mochel, Lisa Emrick, Laura Adang, Penelope Hogarth, Susan J Hayflick, Caleb Rogers, Jae‐Hyeok Lee, Kimberly Burke, Meg Tally Dyer, Donna Stretter Developmental Medicine & Child Neurology.2021; 63(12): 1402. CrossRef
WDR45, one gene associated with multiple neurodevelopmental disorders Yingying Cong, Vincent So, Marina A. J. Tijssen, Dineke S. Verbeek, Fulvio Reggiori, Mario Mauthe Autophagy.2021; 17(12): 3908. CrossRef
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation Robert V.V. Spaull, Audrey K.S. Soo, Penelope Hogarth, Susan J. Hayflick, Manju A. Kurian Tremor and Other Hyperkinetic Movements.2021;[Epub] CrossRef
The roles of iron and HFE genotype in neurological diseases Yunsung Kim, James R. Connor Molecular Aspects of Medicine.2020; 75: 100867. CrossRef
The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System Karina Joppe, Anna-Elisa Roser, Fabian Maass, Paul Lingor Frontiers in Neuroscience.2019;[Epub] CrossRef